|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
no acquisitions reported
|
|
gptkbp:business_model
|
research and development
commercialization of products
|
|
gptkbp:can_lead_to
|
C B4211
C B5138-3
|
|
gptkbp:ceo
|
Gary L. Lichtenstein
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
gptkb:Native_American_tribe
ongoing
Phase 1 trials
Phase 2 trials
completed trials
planned trials
|
|
gptkbp:collaborations
|
gptkb:University
gptkb:Stanford_University
gptkb:University_of_California
academic institutions
pharmaceutical companies
biotech companies
|
|
gptkbp:committee
|
gptkb:battle
|
|
gptkbp:employees
|
approximately 30
|
|
gptkbp:focus
|
mitochondrial therapeutics
|
|
gptkbp:founded
|
gptkb:2009
|
|
gptkbp:founder
|
Joseph A. Rubinfeld
|
|
gptkbp:headquarters
|
gptkb:Menlo_Park,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Coh Bar, Inc.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
multiple patents
|
|
gptkbp:investment
|
gptkb:Company
institutional investors
individual investors
|
|
gptkbp:market_cap
|
approximately $50 million
|
|
gptkbp:partnership
|
gptkb:Research_Institute
|
|
gptkbp:products
|
C B4211
C B5138-3
|
|
gptkbp:publishes
|
peer-reviewed journals
scientific conferences
patent filings
|
|
gptkbp:receives_funding_from
|
government grants
private funding
public offerings
private placements
|
|
gptkbp:regulatory_compliance
|
FDA approval process
|
|
gptkbp:research_areas
|
metabolic diseases
|
|
gptkbp:research_focus
|
gptkb:Company
drug development
obesity
cardiovascular diseases
peptide therapeutics
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:strategic_importance
|
enhance shareholder value
expand product pipeline
increase market presence
|
|
gptkbp:symbol
|
CWBR
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.cohbar.com
|
|
gptkbp:bfsParent
|
gptkb:Verastem,_Inc.
|
|
gptkbp:bfsLayer
|
6
|